Ubenimex

DRACPC ID  DRACPC0059

Active Ingredients   Ubenimex

Description  A microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Ubenimex competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage and bone marrow stem cell as well as stimulates release of interleukin-1 and -2, thus further enhances its antitumor activity.

Synonyms  Bestatin; L-Leucine, N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-, [S-(R*,S*)]-; N-[(2S,3R)-4-phenyl-3-amino-2-hydroxybutyryl]-L-leucine; NK 421; [(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine; [S-(R*,S*)]-N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-L-leucine; Ubenimex

Type  Small Molecule

Disease  Leukemia, Lung cancer, Nasopharyngeal cancer, Hypercholesterolaemia

Classification

  

Aminopeptidases inhibitor Peptide and derivative

Structure Information


Molecular Formula  C16H24N2O4

Molecular Weight  308.37

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid

InChI  InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1

InChI_Key VGGGPCQERPFHOB-RDBSUJKOSA-N

SMILES  CC(C)C[C@H](NC([C@@H](O)[C@H](N)CC1=CC=CC=C1)=O)C(O)=O

External Codes


PubChem CID  72172

DrugBank Accession Number  DB03424

NCI Thesaurus Code  C1015  

UNII  I0J33N5627   GSRS

CAS  58970-76-6



Drug approval


Drug indication
    An adjuvant therapy used for acute and chronic myelonous leukemia, lung cancer and nasopharyngeal cancer. It is also used to treat hypercholesterolaemia.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT02700529 Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA) Lymphedema Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.